Amjevita Injection
Product Images NDC 55513-411

124 FDA label images from Amgen, Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 124 technical images submitted to the FDA as part of the official labeling for Amjevita (NDC 55513-411). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Amjevita 01)

Figure 1 (Amjevita 01)
A line graph showing the percent of ACR 20 responders over time in weeks for AMJEVITA 40 mg every other week compared to placebo. The x-axis represents time in weeks (0 to 48), and the y-axis represents the percent of responders (0 to 70%). The graph shows a higher response rate for AMJEVITA than placebo throughout the study period.*
FDA Label Image

Figure 2 (Amjevita 02)

Figure 2 (Amjevita 02)
A line graph comparing the percentage of ASAS 20 Response over time in weeks between two groups: Placebo (N=107) and Adalimumab (N=208). The graph shows a higher response rate for the Adalimumab group compared to the Placebo group throughout the 24-week period.*
FDA Label Image

Figure 3 (Amjevita 02a)

Figure 3 (Amjevita 02a)
A line graph depicting treatment failure rates over time in months for adalimumab versus placebo. The y-axis represents the percentage of treatment failure, ranging from 0% to 100%, and the x-axis shows time from 0 to 20 months. Two lines illustrate the data: a solid line for placebo and a dashed line for adalimumab treatment, with accompanying numbers of patients at risk below the x-axis.*
FDA Label Image

Figure 3 (Amjevita 02b)

Figure 3 (Amjevita 02b)
A line graph depicting treatment failure rates over time (in months) for placebo and adalimumab treatments. The vertical axis shows treatment failure rate as a percentage, while the horizontal axis shows time in months from 0 to 20. The graph includes a solid line for placebo and a dashed line for adalimumab, with treatment group sizes indicated below the timeline.*
FDA Label Image

Figure 4 (Amjevita 02c)

Figure 4 (Amjevita 02c)
A line chart comparing the probability of failing treatment over time in weeks for adalimumab versus placebo. The x-axis represents time in weeks from 0 to 90, and the y-axis represents the probability of failing treatment from 0 to 1. Adalimumab shows a lower probability of failing treatment over time compared to placebo, which has a higher and steeper probability curve.*
FDA Label Image

Image (Amjevita 03)

Image (Amjevita 03)
An instructional diagram of an AMJEVITA (adalimumab-atto) injection pen showing a blue start button at the top, an expiration date section, a window that indicates medicine presence, and a yellow cap on the bottom. The pen is designed for subcutaneous injection.*
FDA Label Image

Image (Amjevita 04)

Image (Amjevita 04)
An illustrated diagram of the AMJEVITA (adalimumab-atto) subcutaneous injection pen. The pen features a yellow safety guard, a yellow cap that is removed before use, and a yellow window indicating injection completion. The expiration date and a numeric code are shown on the pen label.*
FDA Label Image

Image (Amjevita 05)

Image (Amjevita 05)
An instructional diagram showing a blue injection pen with a yellow cap. The pen has labeled parts including the cap, a window, and the medicine inside. The image highlights the yellow cap on the pen and the visible medicine through the window.*
FDA Label Image

Image (Amjevita 06)

Image (Amjevita 06)
An instructional illustration showing components related to administration of a subcutaneous injection. It includes a blue injection pen device, three cotton balls, an alcohol wipe packet, a skin adhesive bandage, and a red biohazard sharps disposal container with its lid open.*
FDA Label Image

Image (Amjevita 07)

Image (Amjevita 07)
An anatomical diagram showing recommended subcutaneous injection sites for AMJEVITA (adalimumab-atto) on the human body. The illustration highlights the stomach area (abdomen) and thigh as appropriate injection locations for this medication.*
FDA Label Image

Image (Amjevita 08)

Image (Amjevita 08)
Instructional illustration showing a person holding an AMJEVITA injection pen and removing the yellow protective cap from the needle end, demonstrating a step in preparing the adalimumab-atto subcutaneous injection for use.*
FDA Label Image

Image (Amjevita 09)

Image (Amjevita 09)
An instructional illustration showing a person administering a subcutaneous injection to the thigh. The image depicts one hand pinching the skin on the thigh while the other hand presses down, with arrows indicating the direction of skin pinching or injection placement.*
FDA Label Image

Image (Amjevita 10)

Image (Amjevita 10)
AMJEVITA 40 mg/0.8 mL subcutaneous injection vial label by Amgen, Inc. The label shows dosage strength, drug name adalimumab-atto, barcode, lot number, expiration date, and storage instructions. The vial is color-coded with blue and green accents.*
FDA Label Image

Image (Amjevita 11)

Image (Amjevita 11)
An instructional anatomical illustration showing a person pinching the skin of their abdomen, likely demonstrating the technique for subcutaneous injection. The image highlights the skin being lifted between fingers with arrows indicating the pinching and pulling motion.*
FDA Label Image

Image (Amjevita 12)

Image (Amjevita 12)
Illustration showing the proper technique for subcutaneous injection using an injection pen labeled AMJEVITA, demonstrating the pen held at a 90-degree angle to the skin for administration.*
FDA Label Image

Image (Amjevita 13)

Image (Amjevita 13)
An instructional illustration showing a person administering AMJEVITA (adalimumab-atto) via subcutaneous injection using a blue autoinjector. One hand holds the autoinjector perpendicular to the skin, while the other hand stabilizes the injection site.*
FDA Label Image

Image (Amjevita 14)

Image (Amjevita 14)
An instructional illustration showing a blue injection pen being pressed against the skin at an angle, with an arrow pointing downward to indicate the direction of injection for subcutaneous administration.*
FDA Label Image

Image (Amjevita 15)

Image (Amjevita 15)
An instructional illustration showing a hand holding a blue prefilled injection pen labeled with a dosage of 10 mg/.2 mL, positioned above a person's skin on the abdomen, demonstrating the subcutaneous injection process with a 'click' sound effect indicating activation.*
FDA Label Image

Image (Amjevita 16)

Image (Amjevita 16)
An instructional illustration showing a hand holding an injection device vertically and pressing it onto a person's skin, with the other hand stabilizing the injection site. A "click" sound is indicated, suggesting activation of the device for subcutaneous administration.*
FDA Label Image

Image (Amjevita 17)

Image (Amjevita 17)
An instructional illustration showing a blue injection pen with a visible liquid window. A circular timer graphic indicates approximately 10 seconds, likely suggesting the wait time during an injection or preparation step.*
FDA Label Image

Image (Amjevita 18)

FDA Label Image

Image (Amjevita 19)

Image (Amjevita 19)
An instructional illustration showing a hand holding a blue injection pen labeled for AMJEVITA (adalimumab-atto) being placed into a red biohazard sharps disposal container. A black arrow indicates the direction of disposal, emphasizing safe disposal of the injection pen after use.*
FDA Label Image

Image (Amjevita 20)

Image (Amjevita 20)
An instructional diagram of an AMJEVITA injection pen showing labeled parts including a blue start button, expiration date area, a window displaying the medicine inside, and a yellow cap at the bottom of the pen.*
FDA Label Image

Image (Amjevita 21)

Image (Amjevita 21)
An instructional diagram showing recommended subcutaneous injection sites on a human body. The labeled areas for injection include the stomach area (abdomen) and the front of the thighs.*
FDA Label Image

Image (Amjevita 22)

Image (Amjevita 22)
Instructional illustration showing two subcutaneous injection sites for AMJEVITA (adalimumab-atto) injection: the thigh and the abdomen. Each site is depicted with a hand administering an injection using a syringe or pen device, indicating proper injection technique for subcutaneous administration.*
FDA Label Image

Image (Amjevita 23)

Image (Amjevita 23)
An instructional illustration showing a hand holding an Amjevita prefilled syringe, preparing to remove the yellow cap from the needle end. The image depicts the step for syringe preparation prior to subcutaneous injection.*
FDA Label Image

Image (Amjevita 24)

Image (Amjevita 24)
An instructional illustration showing a hand holding a pen-like injector device positioned above the skin, with an arrow pointing downward labeled "Push down," indicating where to press the device for subcutaneous injection.*
FDA Label Image

Image (Amjevita 25)

Image (Amjevita 25)
An instructional illustration demonstrating the use of a subcutaneous injection pen. The image shows a hand holding the pen vertically against the skin of an abdomen, with a "click" sound indicated, signifying activation of the injection device.*
FDA Label Image

Image (Amjevita 26)

Image (Amjevita 26)
An instructional illustration showing the use of a subcutaneous injection device. It depicts one hand holding an injection pen and pressing it against the skin on the forearm with a "click" sound effect. A timer circle indicates a wait period, and a close-up shows the injection window with a yellow indicator.*
FDA Label Image

Image (Amjevita 27)

Image (Amjevita 27)
An instructional diagram illustrating the parts of a prefilled syringe for AMJEVITA (adalimumab-atto) injection. The labeled components include the plunger rod, finger flange, label and expiration date area, syringe barrel containing the medicine, and needle cap on the bottom. This is a subcutaneous injection device.*
FDA Label Image

Image (Amjevita 28)

Image (Amjevita 28)
An illustration showing labeled parts of a used injection syringe for AMJEVITA (adalimumab-atto). The diagram identifies the used plunger rod, finger flange, label and expiration date on the barrel, used syringe barrel, used needle, and needle cap off.*
FDA Label Image

Image (Amjevita 29)

Image (Amjevita 29)
Illustration showing a hand holding alternating doses of prefilled injection syringes from a package, suggesting the use of subcutaneous injection syringes, likely for AMJEVITA (adalimumab-atto) in various available strengths.*
FDA Label Image

Image (Amjevita 30)

Image (Amjevita 30)
An instructional illustration depicting two hands removing an Amjevita 40 mg/.8 mL prefilled syringe from its packaging tray, with red arrows indicating the direction to pull the syringe upwards and out of the tray.*
FDA Label Image

Image (Amjevita 31)

Image (Amjevita 31)
An instructional diagram of a prefilled syringe for Amjevita (adalimumab-atto) injection, showing labeled parts including needle cap on, syringe barrel containing medicine, label and expiration date area, plunger rod, and finger flange for handling.*
FDA Label Image

Image (Amjevita 32)

Image (Amjevita 32)
Illustration showing a subcutaneous injection setup including a prefilled syringe, cotton balls, adhesive bandage, and a red biohazard sharps disposal container. The image represents components commonly used for administering AMJEVITA (adalimumab-atto) injection by subcutaneous route.*
FDA Label Image

Image (Amjevita 33)

Image (Amjevita 33)
An instructional illustration showing recommended injection sites on a human body for subcutaneous administration. Highlighted areas include the stomach (abdomen) and the thigh. The image is relevant for subcutaneous injectable drugs like AMJEVITA (adalimumab-atto).*
FDA Label Image

Image (Amjevita 34)

Image (Amjevita 34)
An instructional illustration showing two hands preparing a syringe for injection. The top hand is pulling the cap off the needle straight up, indicating the removal of a protective cover from the syringe needle, while the bottom hand holds the syringe barrel. This diagram demonstrates safe syringe handling prior to subcutaneous injection.*
FDA Label Image

Image (Amjevita 35)

Image (Amjevita 35)
An instructional illustration showing a person pinching the skin on the abdomen, demonstrating the preparation for a subcutaneous injection likely related to administering the AMJEVITA (adalimumab-atto) injection.*
FDA Label Image

Image (Amjevita 36)

Image (Amjevita 36)
An instructional diagram showing the proper technique for subcutaneous injection. The illustration depicts a hand holding a syringe inserted at a 90-degree angle into the skin, with a dashed line indicating an alternative 45-degree angle for needle insertion.*
FDA Label Image

Image (Amjevita 37)

Image (Amjevita 37)
Illustration showing the administration of Amjevita (adalimumab-atto) injection by subcutaneous injection. The image depicts one hand holding a syringe and injecting into the skin of the abdomen while the other hand stretches the skin, demonstrating the subcutaneous injection technique.*
FDA Label Image

Image (Amjevita 38)

Image (Amjevita 38)
An instructional illustration showing a hand holding a syringe for subcutaneous injection. The syringe is positioned with the needle pointing downward, near the skin of the other hand, indicating the injection technique for AMJEVITA (adalimumab-atto) subcutaneous injection.*
FDA Label Image

Image (Amjevita 39)

Image (Amjevita 39)
Illustration showing a hand placing a syringe with a needle into a red sharps disposal container marked with a biohazard symbol, demonstrating the safe disposal of injection needles.*
FDA Label Image

Image (Amjevita 40)

Image (Amjevita 40)
AMJEVITA 20 mg/0.4 mL subcutaneous injection carton label. The label displays the proprietary name AMJEVITA with the generic name adalimumab-atto. It indicates a single-dose prefilled syringe containing 20 mg/0.4 mL of sterile solution with no preservatives. Storage instructions specify refrigeration at 2°C to 8°C (36°F to 46°F), with warnings against freezing and shaking. The label notes it is for pediatric use in patients 15 to less than 30 kg and is manufactured by Amgen, Inc.*
FDA Label Image

Image (Amjevita 41)

Image (Amjevita 41)
AMJEVITA 40 mg/0.8 mL injection packaging label for subcutaneous use. The label shows the brand and generic name (adalimumab-atto), states it is a sterile solution with no preservative, and includes storage instructions to keep refrigerated at 2 to 8°C. The package contains one single-dose prefilled syringe and is labeled by Amgen, Inc. The label also notes it is not made with natural rubber latex.*
FDA Label Image

Image (Amjevita 42)

Image (Amjevita 42)
AMJEVITA 40 mg/0.8 mL injection in a SureClick Prefilled Autoinjector for subcutaneous use. The sterile solution contains no preservative and is packaged as a single-dose autoinjector. The label includes storage instructions, warnings about storage temperature and handling, and states it is not made with natural rubber latex. Manufactured by Amgen, Inc.*
FDA Label Image

Image (Amjevita 43)

Image (Amjevita 43)
An illustration of a clock face displaying "15-30 minutes" at the center, likely indicating a time duration or waiting period.*
FDA Label Image

Image (Amjevita 44)

Image (Amjevita 44)
Illustration of a calendar page displaying "14 days," likely representing a two-week period or interval.*
FDA Label Image

Image (Amjevita 45)

Image (Amjevita 45)
An instructional diagram showing a sharps disposal container with a lid, alongside illustrations of an alcohol wipe, adhesive bandage, and cotton ball or gauze pad, indicating items used with injections.*
FDA Label Image

Image (Amjevita 46)

Image (Amjevita 46)
An instructional diagram illustrating a prefilled syringe filled with medicine. The syringe is shown in an upright position with a close-up inset highlighting the medicine content within the syringe barrel. The illustration is simple and labeled to identify the medicine.*
FDA Label Image

Image (Amjevita 47)

Image (Amjevita 47)
Diagram showing an injection syringe for AMJEVITA (adalimumab-atto), with an inset zoom detailing the location of the expiration date on the syringe label. The syringe is intended for subcutaneous use.*
FDA Label Image

Image (Amjevita 48)

Image (Amjevita 48)
An anatomical illustration showing recommended subcutaneous injection sites for AMJEVITA (adalimumab-atto) injection. The highlighted areas include the abdomen around the navel (avoiding a 2-inch radius) and the front of both thighs. This diagram guides proper injection placement for subcutaneous administration.*
FDA Label Image

Image (Amjevita 49)

Image (Amjevita 49)
An instructional illustration showing handwashing technique. It depicts two hands with soap bubbles, emphasizing thorough washing by rubbing palms together and between fingers to ensure cleanliness.*
FDA Label Image

Image (Amjevita 50)

Image (Amjevita 50)
An instructional illustration showing a hand pressing on a small pouch or patch placed on a surface, likely demonstrating how to apply or activate the product before use. The image is simple, black-and-white line art, focusing on the hand and the pouch without any visible text or branding.*
FDA Label Image

Image (Amjevita 51)

Image (Amjevita 51)
Illustration showing the preparation for using a subcutaneous injection, depicting a hand removing the cap from a syringe plunger before administering the injection.*
FDA Label Image

Image (Amjevita 52)

Image (Amjevita 52)
An instructional illustration showing a red cylindrical container with its lid open and a blue arrow indicating an object being placed inside, accompanied by a separate small gray cylindrical object positioned near the container's opening.*
FDA Label Image

Image (Amjevita 53)

Image (Amjevita 53)
An instructional illustration showing a hand holding an arm, demonstrating a subcutaneous injection technique, likely related to the administration of AMJEVITA (adalimumab-atto) injection.*
FDA Label Image

Image (Amjevita 54)

Image (Amjevita 54)
An instructional illustration showing a hand holding a syringe at a 45-degree angle to the skin of an arm, demonstrating the proper angle for subcutaneous injection administration.*
FDA Label Image

Image (Amjevita 55)

Image (Amjevita 55)
An instructional illustration showing a hand holding a syringe with a needle, injecting medication subcutaneously into the skin of another hand. An arrow indicates the direction of the injection, demonstrating how to perform a subcutaneous injection typically associated with products like AMJEVITA (adalimumab-atto).*
FDA Label Image

Image (Amjevita 56)

Image (Amjevita 56)
Illustration showing a hand holding a syringe with a needle poised above an open vial with a flip-top cap, indicating the step of drawing medication from the vial before injection. No specific product details are visible in the image.*
FDA Label Image

Image (Amjevita 57)

Image (Amjevita 57)
Illustration showing three irregularly shaped white tablets and a light brown adhesive bandage with perforation holes. This image does not directly depict AMJEVITA, which is a subcutaneous injection, suggesting it may be a generic illustration related to medication or wound care.*
FDA Label Image

Image (Amjevita 58)

Image (Amjevita 58)
An annotated diagram of the AMJEVITA injection pen showing key parts including the light blue start button at the top, expiration date label, a window displaying the plunger and medicine, and a yellow cap at the bottom covering the cream safety guard with the needle inside. The plunger position may vary in the window.*
FDA Label Image

Image (Amjevita 59)

Image (Amjevita 59)
An instructional illustration showing a carton with an insert, accompanied by the text "Refrigerate in carton until ready to use." The image indicates proper storage instructions for the medication.*
FDA Label Image

Image (Amjevita 60)

Image (Amjevita 60)
An illustration of a clock face displaying "15-30 minutes" in the center, indicating a time range for an activity related to the product.*
FDA Label Image

Image (Amjevita 61)

Image (Amjevita 61)
An illustration of a calendar page showing "14 days" in bold black text, indicating a two-week period or interval.*
FDA Label Image

Image (Amjevita 62)

Image (Amjevita 62)
An instructional diagram showing a close-up view of a subcutaneous injection device labeled as containing medicine. The image highlights the medicine compartment within the device, designed for delivery of AMJEVITA adalimumab-atto injection.*
FDA Label Image

Image (Amjevita 63)

Image (Amjevita 63)
An instructional illustration showing the placement of the lot number and expiration date on the side panel of an AMJEVITA (adalimumab-atto) subcutaneous injection pen. The diagram highlights where to find the Expiration date on the product packaging.*
FDA Label Image

Image (Amjevita 64)

Image (Amjevita 64)
An instructional illustration showing a sharps disposal container alongside an alcohol wipe, adhesive bandage, and cotton ball or gauze pad, commonly used for safely handling and disposing of injection materials for subcutaneous drugs like AMJEVITA (adalimumab-atto).*
FDA Label Image

Image (Amjevita 65)

Image (Amjevita 65)
Illustration showing common subcutaneous injection sites on a human body, highlighting areas on the abdomen and the front of the thighs as suitable locations for injection.*
FDA Label Image

Image (Amjevita 66)

Image (Amjevita 66)
An instructional illustration depicting two hands engaged in handwashing, with soap bubbles between the palms. The image visually demonstrates proper hand hygiene technique, likely emphasizing the importance of cleansing before or after administering a subcutaneous injection such as AMJEVITA (adalimumab-atto).*
FDA Label Image

Image (Amjevita 67)

Image (Amjevita 67)
An instructional illustration showing a hand holding and pressing a small, rectangular pad or patch. The image likely demonstrates the correct technique for applying or preparing the product for use.*
FDA Label Image

Image (Amjevita 68)

Image (Amjevita 68)
An instructional illustration showing a hand holding an Amjevita injection pen with a visible window and another hand removing a yellow cap from the pen. The image emphasizes that the window should be visible during this step, indicating proper handling before subcutaneous injection.*
FDA Label Image

Image (Amjevita 69)

Image (Amjevita 69)
An instructional illustration showing proper injection technique for AMJEVITA (adalimumab-atto) subcutaneous injection. It depicts a hand holding an injection pen, pinching the skin at the intended injection site on the arm or hand to prepare for injection.*
FDA Label Image

Image (Amjevita 70)

Image (Amjevita 70)
Instructional diagram showing two steps of a subcutaneous injection process using a pen-type injector. The first panel illustrates the pen pressed against the skin with an arrow indicating downward direction, and the second panel shows the pen after injection with a similar downward arrow.*
FDA Label Image

Image (Amjevita 71)

Image (Amjevita 71)
An instructional illustration showing a hand gripping a device with an arrow above pointing downward, indicating a pressing or pushing action. The image likely demonstrates how to operate or activate a component of a subcutaneous injection device for AMJEVITA (adalimumab-atto).*
FDA Label Image

Image (Amjevita 72)

Image (Amjevita 72)
An instructional illustration showing the use of a subcutaneous injection device. It depicts a hand holding the device poised for injection into the skin, with close-up views highlighting a window on the device transitioning from partially to fully yellow, indicating completion of the injection process.*
FDA Label Image

Image (Amjevita 73)

Image (Amjevita 73)
An instructional illustration showing how to insert a yellow needle into a red vial or container, with a blue and yellow auto-injector pen positioned nearby. The image likely depicts part of the preparation or administration process for the AMJEVITA (adalimumab-atto) subcutaneous injection.*
FDA Label Image

Image (Amjevita 74)

Image (Amjevita 74)
An illustration depicting a beige adhesive bandage with perforations on both ends above three irregularly shaped white cotton balls. The image visually implies wound care or post-injection aftercare typically associated with subcutaneous injections.*
FDA Label Image

Image (Amjevita 75)

Image (Amjevita 75)
An instructional diagram of the Amjevita subcutaneous injection pen showing labeled parts including a light blue start button, expiration date window, needle safety guard with needle inside (yellow cap), a window displaying the medicine and possibly the plunger, highlighting the injection pen's key components.*
FDA Label Image

Image (Amjevita 76)

Image (Amjevita 76)
Illustration showing a medicine carton with an internal flap, accompanied by text advising to refrigerate the carton until ready to use. The image relates to storage instructions for AMJEVITA (adalimumab-atto) injectable product.*
FDA Label Image

Image (Amjevita 77)

Image (Amjevita 77)
An instructional diagram illustrating a clock face with the time indicated as 15-30 minutes, likely representing a time interval for a process or action related to the product use or preparation.*
FDA Label Image

Image (Amjevita 78)

Image (Amjevita 78)
Illustration of a calendar page showing "14 days" prominently, likely used to indicate a two-week interval or duration for medication administration or scheduling.*
FDA Label Image

Image (Amjevita 79)

Image (Amjevita 79)
An instructional diagram showing a blue pen-style injection device with a close-up inset highlighting the medicine window. The label points to the visible medicine inside the device, illustrating its location within the injection pen for AMJEVITA (adalimumab-atto) subcutaneous injection.*
FDA Label Image

Image (Amjevita 80)

Image (Amjevita 80)
An instructional diagram illustrating the location of the expiration date on an Amjevita prefilled injection pen. The expiration date is shown on the side panel near the top of the pen's outer casing, labeled as LOT and Exp.*
FDA Label Image

Image (Amjevita 81)

Image (Amjevita 81)
An instructional illustration showing a sharps disposal container used for safely discarding needles and other sharp medical items. The image also includes depictions of an alcohol wipe, adhesive bandage, and cotton ball or gauze pad, which are common supplies used in subcutaneous injection procedures.*
FDA Label Image

Image (Amjevita 82)

Image (Amjevita 82)
An instructional diagram showing preferred subcutaneous injection sites for AMJEVITA (adalimumab-atto). Highlighted areas on a human silhouette include the abdomen around the navel and the front thighs, indicating where the injection can be administered.*
FDA Label Image

Image (Amjevita 83)

Image (Amjevita 83)
Black and white line drawing illustrating handwashing with soap bubbles around the hands, showing thorough cleaning of both hands together. No text or brand information is visible.*
FDA Label Image

Image (Amjevita 84)

Image (Amjevita 84)
An instructional illustration showing a hand pressing down on a square patch or adhesive. This likely represents the application or adhesion step of a transdermal or injection device related to AMJEVITA (adalimumab-atto) injection for subcutaneous use.*
FDA Label Image

Image (Amjevita 85)

Image (Amjevita 85)
An instructional illustration showing how to hold and prepare a blue subcutaneous injection pen with the label pointing to a 'window' that should be visible. A hand is holding the pen, and another hand is holding a yellow cap, indicating the removal of the cap before injection.*
FDA Label Image

Image (Amjevita 86)

Image (Amjevita 86)
An illustration showing a hand holding a blue injection device for subcutaneous administration. The image instructs to pinch the skin at the injection site before injecting. The injection device is positioned perpendicular to the pinched skin area.*
FDA Label Image

Image (Amjevita 87)

Image (Amjevita 87)
Illustration showing hands holding a blue injection pen device. The first image shows the pen held vertically with an arrow pointing downward. The second image shows the pen slightly tilted to the right, also with a downward arrow, indicating a step in preparing or administering a subcutaneous injection.*
FDA Label Image

Image (Amjevita 88)

Image (Amjevita 88)
Instructional illustration showing a hand gripping a medical device, likely an injection pen, with a downward-pointing arrow above, indicating a pressing or pushing action to administer the subcutaneous injection.*
FDA Label Image

Image (Amjevita 89)

Image (Amjevita 89)
Instructional illustration showing the use of a device for subcutaneous injection. It depicts a hand pressing the injection device onto the skin with a downward arrow indicating the injection action, followed by close-up views of the device's indicator to show proper use completion.*
FDA Label Image

Image (Amjevita 90)

Image (Amjevita 90)
An instructional illustration showing the process of injecting with a pen device into a vial or container. The image depicts a capped injection pen with a needle and a red container with an open lid, indicated by a blue arrow pointing towards the container opening.*
FDA Label Image

Image (Amjevita 91)

Image (Amjevita 91)
An illustration showing a small adhesive bandage above three cotton balls. The bandage is rectangular with rounded corners and has six perforations on each side, typically used for covering injection sites. The cotton balls are irregular in shape, suggesting a medical or injection-related context.*
FDA Label Image

Image (Amjevita 92)

Image (Amjevita 92)
Illustration showing parts of a subcutaneous injection syringe labeled with plunger rod, finger grip, expiration date, syringe body, plunger (variable location), medicine, and needle cap containing the needle inside.*
FDA Label Image

Image (Amjevita 93)

Image (Amjevita 93)
An illustration of a prefilled syringe designed for subcutaneous injection, featuring a yellow plunger and a transparent barrel with a gray needle cap, consistent with common syringe designs for administering biologic drugs such as AMJEVITA (adalimumab-atto).*
FDA Label Image

Image (Amjevita 94)

Image (Amjevita 94)
An illustration of a syringe-style injection device with a blue plunger and a white body, featuring a black and gray grip area at the bottom. This image likely represents a subcutaneous injection device for the drug AMJEVITA (adalimumab-atto).*
FDA Label Image

Image (Amjevita 95)

Image (Amjevita 95)
Illustration of a subcutaneous injection syringe device for AMJEVITA (adalimumab-atto). The syringe is depicted upright with an orange plunger at the top, white body, and gray needle cover at the bottom. No text or dosage information is visible on the device.*
FDA Label Image

Image (Amjevita 96)

Image (Amjevita 96)
An instructional illustration showing a carton with an arrow pointing to it accompanied by the text: Refrigerate in carton until ready to use, indicating storage instructions for the injectable drug AMJEVITA (adalimumab-atto).*
FDA Label Image

Image (Amjevita 97)

Image (Amjevita 97)
An instructional illustration showing a hand removing the cap from a prefilled injection device. The image highlights the upward pulling motion to detach the cap from the syringe prior to subcutaneous injection.*
FDA Label Image

Image (Amjevita 98)

Image (Amjevita 98)
An illustration of a clock face showing the time duration of 15 to 30 minutes, likely indicating a time interval for use or effect related to AMJEVITA injection.*
FDA Label Image

Image (Amjevita 99)

Image (Amjevita 99)
An illustration of a calendar page showing '14 days' in bold typography, representing a two-week time period.*
FDA Label Image

Image (Amjevita 100)

Image (Amjevita 100)
An instructional illustration showing a red sharps disposal container with a lid open, accompanied by labeled drawings of three medical items: an alcohol wipe, an adhesive bandage, and a cotton ball or gauze pad. The image is intended to depict materials associated with safe injection disposal and aftercare.*
FDA Label Image

Image (Amjevita 101)

Image (Amjevita 101)
An instructional illustration showing a subcutaneous injection device with a labeled close-up highlighting the 'Medicine' within the syringe. The diagram indicates the medication portion contained inside the injection apparatus.*
FDA Label Image

Image (Amjevita 102)

Image (Amjevita 102)
An illustration showing a subcutaneous injection device with a magnified inset highlighting the location of the expiration date on the device. The expiration date label is clearly pointed out for user reference.*
FDA Label Image

Image (Amjevita 103)

Image (Amjevita 103)
An instructional illustration showing the recommended subcutaneous injection sites for AMJEVITA (adalimumab-atto). The diagram highlights the abdomen around the navel and the outer thigh areas on a human figure, indicating where the injection can be administered.*
FDA Label Image

Image (Amjevita 104)

Image (Amjevita 104)
An instructional black-and-white line drawing showing two hands being washed with soap bubbles, illustrating proper hand washing technique. No text or labels are visible in the image.*
FDA Label Image

Image (Amjevita 105)

Image (Amjevita 105)
An instructional illustration showing a hand pressing down on a square object, which appears to be an alcohol swab or similar item used to clean skin before injection. This image likely relates to the preparation for subcutaneous administration of AMJEVITA (adalimumab-atto) injection.*
FDA Label Image

Image (Amjevita 106)

Image (Amjevita 106)
Illustration showing two hands holding an injection device and a needle cap. The left hand is gripping the needle cap with an arrow pointing left, indicating removal, while the right hand holds the syringe with the needle exposed, demonstrating how to remove the needle cover from the injection device.*
FDA Label Image

Image (Amjevita 107)

Image (Amjevita 107)
An instructional illustration depicting how to insert a cylindrical object into the opening of a container with a hinged lid. The container is shown open from the top, and a blue arrow indicates the direction to place the object inside the container.*
FDA Label Image

Image (Amjevita 108)

Image (Amjevita 108)
Illustration showing how to pinch the skin at the injection site for a subcutaneous injection. The image depicts a hand gently pinching the skin of the outer arm, indicating the proper technique for administering an injection such as AMJEVITA (adalimumab-atto).*
FDA Label Image

Image (Amjevita 109)

Image (Amjevita 109)
An instructional diagram showing a hand-administered subcutaneous injection at a 45-degree angle. The illustration depicts one hand holding the skin and the other inserting a syringe needle beneath the skin, demonstrating proper injection technique for AMJEVITA (adalimumab-atto) injection.*
FDA Label Image

Image (Amjevita 110)

Image (Amjevita 110)
An instructional illustration showing a hand holding a syringe injecting a substance subcutaneously into the skin of another hand, consistent with subcutaneous injection technique for a product like AMJEVITA (adalimumab-atto).*
FDA Label Image

Image (Amjevita 111)

Image (Amjevita 111)
An instructional illustration showing a hand holding a syringe aimed at the opening of a can, with an arrow indicating insertion of the syringe into the can's tab opening.*
FDA Label Image

Image (Amjevita 112)

Image (Amjevita 112)
An illustration showing two types of adhesive bandages. The top bandage is rectangular with rounded edges and ventilation holes on each side. Below it are three irregularly shaped bandages, suggesting alternative dressing options. The image likely represents common wound care items but includes no branding or text.*
FDA Label Image

Principal Display Panel (20 mg Syringe Carton)

Principal Display Panel (20 mg Syringe Carton)
AMJEVITA 20 mg/0.4 mL subcutaneous injection packaging label. The label shows the adalimumab-atto injection in a prefilled syringe format by Amgen, Inc. Instructions include storing the sterile solution refrigerated at 2°C to 8°C and warnings such as no shaking, freezing, and that it is for pediatric patients 15 kg to less than 30 kg. The label also states it contains 1 single-dose prefilled syringe and is Rx only.*
FDA Label Image

Principal Display Panel (40 mg Syringe Carton)

Principal Display Panel (40 mg Syringe Carton)
AMJEVITA 40 mg/0.8 mL injection label for subcutaneous use. The label includes the product name, generic name adalimumab-atto, and dosage strength. It features storage instructions, manufacturer Amgen, Inc, and a depiction of a syringe. The label also states the product is a sterile solution without preservatives and cautions to protect from light and follow enclosed medication guide instructions.*
FDA Label Image

Principal Display Panel (40 mg Autoinjector Carton)

Principal Display Panel (40 mg Autoinjector Carton)
Packaging label for AMJEVITA (adalimumab-atto) injection, 40 mg/0.8 mL prefilled autoinjector by Amgen, Inc. The label specifies subcutaneous use only, sterile solution with no preservative, refrigeration requirements (2°C to 8°C), and storage precautions including protection from light and avoidance of shaking. The package contains one single-dose SureClick prefilled autoinjector and notes it is not made with natural rubber latex.*
FDA Label Image

Principal Display Panel (10 mg/0.2 mL Syringe Carton)

Principal Display Panel (10 mg/0.2 mL Syringe Carton)
AMJEVITA 10 mg/0.2 mL is a subcutaneous injection available as a single-dose prefilled syringe. The packaging highlights that it is a sterile solution with no preservative, requires refrigeration between 2°C to 8°C (36°F to 46°F), and should not be frozen or shaken. It is labeled for pediatric use for patients weighing 10 to less than 15 kg, and it includes warnings about the enclosed medication guide and storage instructions. The labeler is Amgen, Inc.*
FDA Label Image

Principal Display Panel (20 mg/0.2 mL Syringe Carton)

Principal Display Panel (20 mg/0.2 mL Syringe Carton)
Label for AMJEVITA 20 mg/0.2 mL injection, adalimumab-atto, a human prescription drug by Amgen, Inc. The label specifies it is a single-dose prefilled syringe for subcutaneous use, stored refrigerated at 2°C to 8°C. It highlights no preservatives, no natural rubber latex, and pediatric use for patients 15 to less than 30 kg.*
FDA Label Image

Principal Display Panel (40 mg/0.4 mL Syringe Carton)

Principal Display Panel (40 mg/0.4 mL Syringe Carton)
AMJEVITA 40 mg per 0.4 mL injection label for a human prescription drug containing adalimumab-atto. The label indicates a single-dose prefilled syringe for subcutaneous use only. It includes storage instructions to refrigerate at 2°C to 8°C and warnings about no preservatives and handling precautions. The labeler is Amgen, Inc.*
FDA Label Image

Principal Display Panel (80 mg Syringe Carton)

Principal Display Panel (80 mg Syringe Carton)
Box packaging label for AMJEVITA 80 mg/0.8 mL subcutaneous injection by Amgen, Inc. The label includes product name, strength, dosage form, single-dose prefilled syringe illustration, storage instructions to refrigerate at 2°C to 8°C, and warnings about preservative-free solution and latex content.*
FDA Label Image

Principal Display Panel (40 mg/0.4 mL Autoinjector Carton)

Principal Display Panel (40 mg/0.4 mL Autoinjector Carton)
The packaging label for AMJEVITA (adalimumab-atto) injection, 40 mg per 0.4 mL, by Amgen, Inc. It is a single-dose prefilled SureClick autoinjector. The label includes storage instructions to refrigerate at 2°C to 8°C and not to freeze or shake, and notes the product is a sterile solution with no preservative and is for subcutaneous use only. The label also states it is not made with natural rubber latex and includes a barcode and caution to consult accompanying documents.*
FDA Label Image

Principal Display Panel (80 mg Autoinjector Carton)

Principal Display Panel (80 mg Autoinjector Carton)
AMJEVITA 80 mg/0.8 mL injection by Amgen, Inc, is shown in packaging for a single-dose prefilled SureClick autoinjector. The label highlights subcutaneous use, sterile solution with no preservative, and storage instructions between 2°C to 8°C. The product is not made with natural rubber latex and includes cautions for use and storage.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.